Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Carcinoma: Analysis of 30-Day Morbidity and Mortality
The aim of this study was to evaluate morbidity and mortality associated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovarian, fallopian tube, and primary peritoneal cancer.
A retrospective review of patients undergoing cytoreductive surgery plus HIPEC from 1 January 2007 to 29 July 2013 at two academic medical centers was performed. Grade 3/4 complications (National Cancer Institute’s Common Toxicity Criteria version 4.0) from day of surgery until 30 days postoperatively were recorded.
Thirty-two patients were identified, with 27 cases of ovarian cancer, three primary peritoneal cancers, and two fallopian tube cancers. Indications included 24 at the time of cancer recurrence, six at interval surgical resection, and two in the consolidative setting. Hyperthermic chemotherapeutic regimens included carboplatin (n = 21), cisplatin (n = 4), oxaliplatin (n = 2), oxaliplatin + intravenous 5-fluorouracil (n = 1), doxorubicin (n = 1), and cisplatin + doxorubicin (n = 1). Infusion time ranged from 30 to 90 min, with a maximum temperature range of 41–43 °C. The combined grade 3/4 morbidity rate was 65.6 %, and the most frequent morbidities included grade 3 anemia (40.6 %), infection (15.6 %), and pleural effusion (12.5 %). Six patients required readmission (18.8 %), and two patients required reoperation (6.2 %). Full-thickness diaphragm resection/peritoneal stripping had a significant association with grade 3/4 pleural effusions (p = 0.0007).
Cytoreductive surgery plus HIPEC is feasible in patients with ovarian cancer with 65.6 % grade 3/4 morbidity and no deaths. Balancing these complications with potential survival benefits is important in centers considering implementing HIPEC protocols.
KeywordsOxaliplatin Epithelial Ovarian Cancer Intraperitoneal Chemotherapy Peritoneal Cancer Index Hyperthermic Intraperitoneal Chemotherapy
James Cripe, Jill Tseng, Ramez Eskander, Amanda Nickles Fader, Edward Tanner, Robert Bristow have no financial or non-financial disclosures.
- 2.Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194–200. doi: 10.1200/JCO.2003.02.153.PubMedCrossRefGoogle Scholar
- 9.Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol. 2007;18(12):1943–50. doi: 10.1093/annonc/mdm137.PubMedCrossRefGoogle Scholar
- 12.Di Giorgio A, Naticchioni E, Biacchi D, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113(2):315–25. doi: 10.1002/cncr.23553.PubMedCrossRefGoogle Scholar
- 14.Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007;197(6):676.e1–7. doi: 10.1016/j.ajog.2007.10.495.
- 15.Bashir S, Gerardi MA, Giuntoli RL, Montes TPD, Bristow RE. Surgical technique of diaphragm full-thickness resection and trans-diaphragmatic decompression of pneumothorax during cytoreductive surgery for ovarian cancer. Gynecol Oncol. 2010;119(2):255–8. doi: 10.1016/j.ygyno.2010.07.017.PubMedCrossRefGoogle Scholar
- 19.Cascales-Campos PA, Gil J, Gil E, et al. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer. Ann Surg Oncol. 2014;21(7):2383–2389. doi: 10.1245/s10434-014-3599-4.PubMedCrossRefGoogle Scholar
- 21.Chua T, Robertson G, Liauw W. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009;135(12):1637–45. doi: 10.1007/s00432-009-0667-4.PubMedCrossRefGoogle Scholar
- 22.Bakrin N, Gilly FN, Baratti D, et al. Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients. Eur J Surg Oncol. 2013;39(7):742–7. doi: 10.1016/j.ejso.2013.02.018.PubMedCrossRefGoogle Scholar
- 23.Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39(12):1435–43. doi: 10.1016/j.ejso.2013.09.030.PubMedCrossRefGoogle Scholar
- 24.Bakrin N, Cotte E, Golfier F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol. 2012;19(13):4052–8. doi: 10.1245/s10434-012-2510-4.PubMedCrossRefGoogle Scholar
- 28.ClinicalTrials.gov., a service of the US National Institutes of Health. https://clinicaltrials.gov/ct2/results?term=HIPEC%2C+ovarian+cancer&show_down=Y. Accessed 27 Jun 2014.
- 31.Carrabin N, Mithieux F, Meeus P. Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bull Cancer. 2010;97:1–10. Available at: http://www.jle.com/e-docs/00/04/57/15/article.phtml. Accessed 27 Jul 2014.